<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04528680</url>
  </required_header>
  <id_info>
    <org_study_id>NU 20C03</org_study_id>
    <nct_id>NCT04528680</nct_id>
  </id_info>
  <brief_title>Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel for Recurrent Glioblastoma</brief_title>
  <acronym>SC9/ABX</acronym>
  <official_title>Phase 1 / 2 Trial of Blood-brain Barrier Opening With an Implantable Ultrasound Device SonoCloud-9 and Treatment With Albumin-bound Paclitaxel in Patients With Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CarThera</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lantheus Medical Imaging</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Paclitaxel is among the most active agents against glioblastoma in preclinical models.&#xD;
      However, its clinical use has been hampered by the blood-brain barrier (BBB). In this trial&#xD;
      we will implant a novel device with 9 ultrasound emitters allowing to temporarily and&#xD;
      reversibly open the BBB immediately prior to chemotherapy infusion with albumin-bound&#xD;
      paclitaxel.&#xD;
&#xD;
      In this phase 1 trial increasing doses of chemotherapy will be delivered as long deemed safe&#xD;
      and prior patient had not experienced severe toxicity. Once the the recommended dosing has&#xD;
      been established, additional patients will be treated in order to better evaluate the&#xD;
      antitumor efficacy of this novel treatment.&#xD;
&#xD;
      The device will be implanted at the time of surgical resection of the recurrent tumor. During&#xD;
      that procedure a first test dose of the chemotherapy will be administered in the operating&#xD;
      room after sonication (procedure of activating ultrasound and opening the BBB) and tissue&#xD;
      concentrations in different parts of the resected tumor will be measured. In select patients,&#xD;
      the sonication procedure will occur immediately after the test dose of chemotherapy is&#xD;
      administered.&#xD;
&#xD;
      The objectives of this trial are to establish a safe and effective dose of ABX, to&#xD;
      demonstrate that the opening of the BBB increases chemotherapy concentration in the tumor,&#xD;
      and to estimate how effective this treatment is in reducing the tumor burden and prolonging&#xD;
      life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will undergo craniotomy for tumor resection. During the tumor resection, an&#xD;
      initial low dose of paclitaxel will be given following sonication. In select patients, the&#xD;
      sonication procedure will occur immediately after the test dose of chemotherapy is&#xD;
      administered.The sonication device will be implanted at the end of the procedure. About two&#xD;
      weeks after surgery, patients will undergo sonication and albumin-bound paclitaxel&#xD;
      administration with MRI to quantify extent of blood brain barrier opening. Sonication and&#xD;
      administration of albumin-bound paclitaxel will continue every 3 weeks until disease&#xD;
      progression. The planned ABX starting dose is 40 mg/m2 of ABX, to be escalated in the absence&#xD;
      of significant toxicity up to 260 mg/m2. Blood samples for circulating tumor DNA will also be&#xD;
      collected before and after each sonication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>1st treatment cycle = 3 weeks</time_frame>
    <description>Occurrence of ≥ grade 3 treatment related toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1-year survival rate</measure>
    <time_frame>12-months</time_frame>
    <description>Survival time from date of tumor resection and device implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of side effects/toxicity associated with Sonication/ABX treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Safety and tolerance</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Extent of tumor and peritumoral tissue covered by BBB opening</measure>
    <time_frame>1st cycle (cycle = 3 weeks)</time_frame>
    <description>increase in Gd contrast enhancement post sonication</description>
  </other_outcome>
  <other_outcome>
    <measure>Objective response rate (RANO)</measure>
    <time_frame>6 months</time_frame>
    <description>measurement of tumor shrinkage (if there is residual disease)</description>
  </other_outcome>
  <other_outcome>
    <measure>Measurement of circulating tumor DNA, methods and units for this measure are to be determined and still under evaluation.</measure>
    <time_frame>1st cycle, cycles 2 - 6 as applicable (cycle = 3 weeks)</time_frame>
    <description>compare before and after sonication</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Gliosarcoma</condition>
  <condition>GBM</condition>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Glioblastoma, IDH-wildtype</condition>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>SC9/ABX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of albumin-bound paclitaxel immediately followed by sonication using the SC9 device and microbubbles in order to open the blood-brain barrier.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sonication for opening of blood-brain barrier</intervention_name>
    <description>Implantation of SC-9 device and repeat activation of 9 ultrasound emitters during i.v. injection of microbubbles</description>
    <arm_group_label>SC9/ABX</arm_group_label>
    <other_name>SonoCloud-9 device, SC-9</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy, albumin-bound paclitaxel</intervention_name>
    <description>Intravenous infusion of ABX over 30 minutes</description>
    <arm_group_label>SC9/ABX</arm_group_label>
    <other_name>Abraxane®</other_name>
    <other_name>ABX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of Isocitrate Dehydrogenase 1 (IDH1) wild-type glioblastoma on&#xD;
             pathology from initial surgery (e.g. IDH R132H neg)&#xD;
&#xD;
          2. Ability to undergo contrast-enhanced MRI&#xD;
&#xD;
          3. Radiographic evidence of tumor recurrence/progression after failure of 1 - 2 lines of&#xD;
             prior therapy&#xD;
&#xD;
          4. Measurable or evaluable disease&#xD;
&#xD;
               1. Measurable: contrast-enhancement (bidirectional diameters ≥ 1cm) on MRI&#xD;
&#xD;
               2. Non-measurable/evaluable: contrast-enhancement diameters &lt; 1 cm&#xD;
&#xD;
          5. Maximal tumor diameter pre-surgery ≤ 70 mm on T1wMRI&#xD;
&#xD;
          6. Candidate for at least partial surgical resection&#xD;
&#xD;
          7. Greater 12 weeks from completion of radiation therapy&#xD;
&#xD;
          8. Age ≥ 18 years&#xD;
&#xD;
          9. Stable or decreasing dose of corticosteroids equivalent to ≤ 6 mg dexamethasone, for ≥&#xD;
             7 days prior to registration&#xD;
&#xD;
         10. WHO performance status ≤ 2 (equivalent to Karnofsky Performance Status (KPS) of ≥70)&#xD;
&#xD;
         11. Adequate hepatic, renal and bone marrow function, documented with normal laboratory&#xD;
             values or no more than grade 1 outside the norm performed within 14 days prior to&#xD;
             registration&#xD;
&#xD;
         12. For patients with a childbearing potential&#xD;
&#xD;
               1. Negative pregnancy test within 14 days prior to registration&#xD;
&#xD;
               2. Agreement to use adequate contraception for the duration of study participation,&#xD;
                  and for 3 and 6 months after the last dose of nab-paclitaxel for men and women of&#xD;
                  childbearing potential, respectively.&#xD;
&#xD;
         13. Have the ability to understand and the willingness to sign a written informed consent&#xD;
             prior to registration on study&#xD;
&#xD;
         14. Be willing and able to comply with the protocol for the duration of the study&#xD;
&#xD;
         15. Provide written, signed and dated informed consent prior to study registration. NOTE:&#xD;
             no study-specific screening procedures may be performed until written consent has been&#xD;
             obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have multifocal disease that cannot be encompassed in the ultrasound fields:&#xD;
&#xD;
               1. e.g. &gt; 70-mm apart&#xD;
&#xD;
               2. tumor located in the posterior fossa&#xD;
&#xD;
          2. Patients at risk of cranial wound dehiscence&#xD;
&#xD;
          3. Have uncontrolled epilepsy or require treatment with enzyme-inducing antiepileptics&#xD;
&#xD;
          4. Have clinical evidence of peripheral neuropathy on examination&#xD;
&#xD;
          5. Have received any other investigational agents within 4 weeks of registration&#xD;
&#xD;
          6. Have received prior therapy with or have history of allergic reactions attributed to&#xD;
             compounds of similar chemical or biologic composition to paclitaxel&#xD;
&#xD;
          7. Medical contraindications to Abraxane®&#xD;
&#xD;
          8. Have an uncontrolled intercurrent illness&#xD;
&#xD;
          9. Are pregnant or nursing&#xD;
&#xD;
         10. Have a history of active malignancy within 3 years prior to registration.&#xD;
&#xD;
         11. Have a known history of hypersensitivity reactions to perflutren lipid microsphere&#xD;
             components or to any of the inactive ingredients in Definity® (the FDA-approved&#xD;
             ultrasound contrast agent to be used in this study)&#xD;
&#xD;
         12. Patients with coils, clips, shunts, intravascular stents, and/or non-removable wafer,&#xD;
             non resorbable dura substitute, or reservoirs.&#xD;
&#xD;
         13. Patients with medical need to continue antiplatelet therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Stupp, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam M Sonabend, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christina Amidei, APN, PhD</last_name>
    <phone>(312) 695-9124</phone>
    <email>christina.amidei@nm.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roger Stupp, MD</last_name>
    <email>roger.stupp@northwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanna Davis, BSN, RN</last_name>
      <phone>312-926-9441</phone>
      <email>Shanna.Davis@nm.org</email>
    </contact>
    <contact_backup>
      <last_name>Christina Amidei, PhD, APN</last_name>
      <phone>(312) 695-9124</phone>
      <email>christina.amidei@nm.org</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M Sonabend, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roger Stupp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karan Dixit, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Priya Kumthekar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rimas V Lukas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Idbaih A, Canney M, Belin L, Desseaux C, Vignot A, Bouchoux G, Asquier N, Law-Ye B, Leclercq D, Bissery A, De Rycke Y, Trosch C, Capelle L, Sanson M, Hoang-Xuan K, Dehais C, Houillier C, Laigle-Donadey F, Mathon B, André A, Lafon C, Chapelon JY, Delattre JY, Carpentier A. Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma. Clin Cancer Res. 2019 Jul 1;25(13):3793-3801. doi: 10.1158/1078-0432.CCR-18-3643. Epub 2019 Mar 19.</citation>
    <PMID>30890548</PMID>
  </reference>
  <reference>
    <citation>Sonabend AM, Stupp R. Overcoming the Blood-Brain Barrier with an Implantable Ultrasound Device. Clin Cancer Res. 2019 Jul 1;25(13):3750-3752. doi: 10.1158/1078-0432.CCR-19-0932. Epub 2019 May 10.</citation>
    <PMID>31076548</PMID>
  </reference>
  <reference>
    <citation>Zhang DY, Dmello C, Chen L, Arrieta VA, Gonzalez-Buendia E, Kane JR, Magnusson LP, Baran A, James CD, Horbinski C, Carpentier A, Desseaux C, Canney M, Muzzio M, Stupp R, Sonabend AM. Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations. Clin Cancer Res. 2020 Jan 15;26(2):477-486. doi: 10.1158/1078-0432.CCR-19-2182. Epub 2019 Dec 12.</citation>
    <PMID>31831565</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Adam Sonabend</investigator_full_name>
    <investigator_title>Assistant Professor, Feinberg School of Medicine, Neurological Surgery</investigator_title>
  </responsible_party>
  <keyword>ultrasound</keyword>
  <keyword>SonoCloud</keyword>
  <keyword>blood-brain barrier</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>albumin-bound paclitaxel</keyword>
  <keyword>Abraxane®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

